Kidney Disease & Dialysis

PATH-2 | 2023–2025

Phase 3 study evaluating dose-titrated PLS240 for the treatment of secondary
hyperparathyroidism in individuals with end-stage kidney disease receiving hemodialysis.
Role: Site Principal Investigator

REGEN-007 | 2022–2025

Study of renal autologous cell therapy (REACT®) in patients with Type 1 or Type 2 diabetes
and chronic kidney disease.
Role: Site Principal Investigator

APPLAUSE-IgAN | 2021–2024

Phase 3 multicenter study evaluating LNP023 (iptacopan) in patients with primary IgA
nephropathy.
Role: Site Principal Investigator

GFB-887 Study | 2021–2022

Phase 2a study evaluating GFB-887 in patients with diabetic nephropathy, focal segmental
glomerulosclerosis (FSGS), and treatment-resistant minimal change disease.
Role: Site Principal Investigator

BI 685509 Study | 2021–2023

Randomized, placebo-controlled study evaluating BI 685509 and its effect on UACR in
patients with non-diabetic kidney disease.
Role: Site Principal Investigator

Vadadustat Hemodialysis Study | 2021–2023

Study evaluating conversion from a long-acting erythropoiesis-stimulating agent to oral
vadadustat for maintenance treatment of anemia in patients receiving hemodialysis.
Role: Site Principal Investigator

DIALIZE | 2021–2024

International randomized study evaluating sodium zirconium cyclosilicate and arrhythmia-
related cardiovascular outcomes in patients receiving chronic hemodialysis with recurrent
hyperkalemia.
Role: Site Principal Investigator